Related Experiment Video
Updated: Dec 27, 2025
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
Published on: June 7, 2020
Clinical Value of Susceptibility Weighted Imaging of Brain Metastases
Daniel Schwarz1, Martin Bendszus1, Michael O Breckwoldt1,2
1Neuroradiology Department, University Hospital Heidelberg, Heidelberg, Germany.
Abstract:
MRI is used for screening, initial diagnosis and follow-up of brain metastases. Multiparametric MRI protocols encompass an array of image sequences to depict key aspects of metastases morphology and biology. Given the recent safety concerns of Gd-administration and the retention of linear Gd-agents in the brain, non-contrast sequences are currently evaluated regarding their diagnostic value for brain imaging studies. Susceptibility weighted imaging has been established as a valuable clinical and research tool that is heavily used in clinical practice and utilized in diverse pathologies ranging from neuroinflammation, neurovascular disease to neurooncology. We review the value of SWI in the field of brain metastases with an emphasis on its role in early diagnosis, determination of the primary tumor entity, treatment monitoring and discuss therapy-associated changes that can affect SWI. We also review recent insights on the role of "isolated SWI signals" and the controversy on the specificity of SWI for the early detection of brain metastases.
Insights
Susceptibility weighted imaging (SWI) shows promise for diagnosing brain metastases without contrast agents, aiding early detection and treatment monitoring. Further research is needed to clarify its specificity and role in neurooncology.
Area of Science:
- Neuroimaging
- Oncology
- Radiology
Background:
- Magnetic Resonance Imaging (MRI) is crucial for brain metastases management.
- Gadolinium (Gd)-based contrast agents raise safety concerns due to brain retention.
- Non-contrast MRI sequences are being explored for diagnostic utility.
Purpose of the Study:
- To review the diagnostic value of Susceptibility Weighted Imaging (SWI) in brain metastases.
- To emphasize SWI's role in early diagnosis, primary tumor identification, and treatment monitoring.
- To discuss therapy-associated changes and the specificity of SWI signals.
Main Methods:
- Review of existing literature on SWI in brain metastases.
- Analysis of SWI's application in neurooncology, neuroinflammation, and neurovascular disease.
- Evaluation of multiparametric MRI protocols and non-contrast sequences.
Main Results:
- SWI is a valuable tool in clinical practice for various neurological pathologies.
- SWI aids in depicting metastases morphology and biology.
- The role of isolated SWI signals and SWI specificity for early detection is debated.
Conclusions:
- SWI offers significant potential for brain metastases imaging, especially in the context of contrast agent safety.
- SWI can assist in early diagnosis, determining primary tumor origin, and monitoring treatment response.
- Further investigation is required to establish the definitive role and specificity of SWI in neurooncology.
